Nirvana Life Sciences Inc. (CNSX: NIRV.X)
Health Care · Pharmaceuticals · CA
CA$0.03
-40.00% today · -64.7% 1Y
Nirvana Life Sciences Inc. (CNSX: NIRV.X) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $493.30K.
Over the last twelve months the share price has lost 64.7%, trading between 0.01 and 0.14.
Tweenvest scores Nirvana Life Sciences Inc. across four factors: quality 8/100. Its strongest factor is quality.
NIRV.X price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $493.30K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -0.99
- 52-week high
- CA$0.14
- 52-week low
- CA$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 22.92M
- Employees
- —
- Next earnings
- —
About Nirvana Life Sciences Inc.
Nirvana Life Sciences Inc. engages in the scientific research and development of therapeutic products derived from psychedelics. It also focuses on developing methodologies for extraction and purification of psychoactive compounds; and the improvement of propagation techniques for growing such biomass on a large scale. The company was incorporated in 2020 and is headquartered in Vancouver, Canada.
- Listed since
- Mar 18, 2022
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.16 | +0.34% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.18 | -0.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.30 | -1.41% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.00 | -1.14% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.23% |
Figures last refreshed Aug 18, 2026.